вторник, 31 мая 2016 г.

U.S. Supreme Court rejects patent appeal over Cubicin drug

U.S. Supreme Court rejects patent appeal over Cubicin drug


May 31 The U.S. Supreme Court on Tuesday rejected Cubist Pharmaceuticals Inc's bid to revive four patents for its antibiotic drug Cubicin, paving the way for rival Hospira Inc to introduce a generic version as soon as this year. The high court left in place a November ruling by the U.S. Court of Appeals for the Federal Circuit upholding a lower court ruling invaliding four of five patents held by Merck & Co Inc-owned Cubist, which were challenged by Pfizer Inc-owned Hospira.



from Biotech News